Advertisement

External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis

  • Nolwenn Astruc
    Affiliations
    Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest F-29609, France
    Search for articles by this author
  • Jean-Christophe Ianotto
    Affiliations
    Oncology & Haematology Institute, Brest University Hospital, Brest F-29609, France

    Brest University (Université de Bretagne Occidentale), Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Brest F-29609, France
    Search for articles by this author
  • Jean-Philippe Metges
    Affiliations
    Oncology & Haematology Institute, Brest University Hospital, Brest F-29609, France
    Search for articles by this author
  • Karine Lacut
    Affiliations
    Brest University (Université de Bretagne Occidentale), Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Brest F-29609, France

    Centre d'Investigation Clinique INSERM 1412, Brest University Hospital, Brest F-29609, France
    Search for articles by this author
  • Aurélien Delluc
    Correspondence
    Corresponding author at: EA 3878, Département de Médecine interne et de pneumologie, Centre hospitalier universitaire de Brest, Hôpital de la Cavale Blanche, 29609, Brest Cedex, France.
    Affiliations
    Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest F-29609, France

    Brest University (Université de Bretagne Occidentale), Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Brest F-29609, France
    Search for articles by this author
Published:August 31, 2016DOI:https://doi.org/10.1016/j.ejim.2016.08.001
      Venous thromboembolism (VTE) and cancer are two major public health issues that are closely linked. Cancer is part of the major risk factors for VTE and it is estimated that up to 20% of cancer patients will face a VTE issue during the course of their malignancy [
      • Chew H.K.
      • Wun T.
      • Harvey D.
      • Zhou H.
      • White R.H.
      Incidence of venous thromboembolism and its effect on survival among patients with common cancers.
      ,
      • Heit J.A.
      • Silverstein M.D.
      • Mohr D.N.
      • Petterson T.M.
      • O'Fallon W.M.
      • Melton III, L.J.
      Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.
      ]. Patients who develop VTE during the course of their malignancy are at high risk for VTE recurrence: 10 to 17% of them will experience a new VTE event within the first six months of anticoagulation [
      • Carrier M.
      • Cameron C.
      • Delluc A.
      • Castellucci L.
      • Khorana A.A.
      • Lee A.Y.
      Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis.
      ]. However, this risk varies depending on several parameters such as cancer site, cancer histology, or cancer stage [
      • Louzada M.L.
      • Majeed H.
      • Dao V.
      • Wells P.S.
      Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chew H.K.
        • Wun T.
        • Harvey D.
        • Zhou H.
        • White R.H.
        Incidence of venous thromboembolism and its effect on survival among patients with common cancers.
        Arch Intern Med. 2006; 166: 458-464
        • Heit J.A.
        • Silverstein M.D.
        • Mohr D.N.
        • Petterson T.M.
        • O'Fallon W.M.
        • Melton III, L.J.
        Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.
        Arch Intern Med. 2000; 160: 809-815
        • Carrier M.
        • Cameron C.
        • Delluc A.
        • Castellucci L.
        • Khorana A.A.
        • Lee A.Y.
        Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis.
        Thromb Res. 2014; 134: 1214-1219
        • Louzada M.L.
        • Majeed H.
        • Dao V.
        • Wells P.S.
        Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies.
        Blood Coagul Fibrinolysis. 2011; 22: 86-91
        • Louzada M.L.
        • Carrier M.
        • Lazo-Langner A.
        • Dao V.
        • Kovacs M.J.
        • Ramsay TO
        • et al.
        Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
        Circulation. 2012; 126: 448-454
        • Ahn S.
        • Lim K.S.
        • Lee Y.S.
        • Lee J.L.
        Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score.
        Support Care Cancer. 2013; 21: 2309-2313
        • den Exter P.L.
        • Kooiman J.
        • Huisman M.V.
        Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis.
        J Thromb Haemost. 2013; 11: 998-1000